In this article (Cancer Prev Res 2012;6:822–33), which was published in the June 2012 issue of Cancer Prevention Research (1), the authors neglected to include an acknowledgment of individuals who conducted the synthesis of the compound used in the study. The authors apologize for the omission. The acknowledgment is as follows:
Acknowledgments
The authors thank Drs. Robert Reynolds, Bini Mathew, and Kocharani Jacob from Southern Research for the synthesis of sulindac benzylamine and other technical support.
References
1.
Whitt
JD
, Li
N
, Tinsley
HN
, Chen
X
, Zhang
W
, Li
Y
, et al A novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and β-catenin transcriptional activity
. Cancer Prev Res
2012
;5
:822
–33
.©2012 American Association for Cancer Research.
2012
RSS Feeds